Affiliation: University of Ottawa
Le T, Latifah H, Jolicoeur L, Weberpals J, Faught W, Hopkins L, et al
. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?. Gynecol Oncol. 2011;121:451-4 pubmed publisher
..4, p=0.56). Estimated mean survival was 68.9 months in the IV group and 37.5 months in the IP group (p=0.85). Survival benefit associated with IP chemotherapy after optimal upfront surgery may not translate to the neoadjuvant setting. ..
Le T, Latifah H, Jolicoeur L, Faught W, Weberpals J, Hopkins L, et al
. Comparative study of grade 3/4 toxicity associated with intraperitoneal chemotherapy administered after primary versus interval surgical debulking in ovarian cancer. Int J Gynecol Cancer. 2011;21:811-5 pubmed publisher
..Toxicity data can be used to plan for optimal IP chemotherapy delivery, patient counseling, and ongoing supportive care. ..
Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer. 2006;16:986-90 pubmed
..97, 95% CI 1.01-3.87, P= 0.048). The estimated median survival was 50.66 months (95% CI 46.12-55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease...
Le T, Williams K, Senterman M, Hopkins L, Faught W, Fung Kee Fung M. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol. 2007;14:2649-53 pubmed
..47). Upper abdominal disease location and its response to chemotherapy were independent prognostic factors for progression-free survival. Aggressive upper abdominal debulking procedures are recommended to improve oncologic outcomes. ..
Le T, Menard C, Hicks Boucher W, Hopkins L, Weberpals J, Fung Kee Fung M. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol. 2007;106:579-84 pubmed
..To investigate the activity of 5% Imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3...